MX343894B - Síntesis y uso de inhibidores de cinasa. - Google Patents

Síntesis y uso de inhibidores de cinasa.

Info

Publication number
MX343894B
MX343894B MX2012014986A MX2012014986A MX343894B MX 343894 B MX343894 B MX 343894B MX 2012014986 A MX2012014986 A MX 2012014986A MX 2012014986 A MX2012014986 A MX 2012014986A MX 343894 B MX343894 B MX 343894B
Authority
MX
Mexico
Prior art keywords
synthesis
fak
based catalyst
kinase inhibitors
reactions
Prior art date
Application number
MX2012014986A
Other languages
English (en)
Spanish (es)
Other versions
MX2012014986A (es
Inventor
Lei Yixiong
Henry Behrens Carl
Li Hui-Yin
L Sun Connie
Original Assignee
Poniard Pharmaceuticals Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc * filed Critical Poniard Pharmaceuticals Inc *
Publication of MX2012014986A publication Critical patent/MX2012014986A/es
Publication of MX343894B publication Critical patent/MX343894B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2012014986A 2010-06-30 2011-06-28 Síntesis y uso de inhibidores de cinasa. MX343894B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35994210P 2010-06-30 2010-06-30
PCT/US2011/042169 WO2012012139A1 (en) 2010-06-30 2011-06-28 Synthesis and use of kinase inhibitors

Publications (2)

Publication Number Publication Date
MX2012014986A MX2012014986A (es) 2013-07-03
MX343894B true MX343894B (es) 2016-11-28

Family

ID=45497129

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012014986A MX343894B (es) 2010-06-30 2011-06-28 Síntesis y uso de inhibidores de cinasa.

Country Status (10)

Country Link
US (1) US9505719B2 (cg-RX-API-DMAC7.html)
EP (1) EP2588476A4 (cg-RX-API-DMAC7.html)
JP (1) JP5923499B2 (cg-RX-API-DMAC7.html)
CN (1) CN103168037A (cg-RX-API-DMAC7.html)
AU (1) AU2011280031B2 (cg-RX-API-DMAC7.html)
CA (1) CA2803005A1 (cg-RX-API-DMAC7.html)
MX (1) MX343894B (cg-RX-API-DMAC7.html)
NZ (1) NZ604801A (cg-RX-API-DMAC7.html)
WO (1) WO2012012139A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201300012B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110773A1 (en) 2011-02-17 2012-08-23 Cancer Therapeutics Crc Pty Limited Fak inhibitors
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
WO2026086879A1 (zh) * 2024-10-25 2026-04-30 应世生物科技(南京)有限公司 Fak抑制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656182A (en) * 1983-12-06 1987-04-07 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US20040006005A1 (en) 2002-07-02 2004-01-08 Sanjay Bhanot Use of integrin-linked kinase inhibitors for treating insulin resistance, hyperglycemia and diabetes
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
BR0114814A (pt) 2000-10-11 2005-01-25 Cephalon Inc Composições compreendendo composto de modafinila e seu uso
AR040456A1 (es) * 2002-06-27 2005-04-06 Bristol Myers Squibb Co Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
US20080119515A1 (en) 2003-03-10 2008-05-22 M Arshad Siddiqui Heterocyclic Kinase Inhibitors: Methods of Use and Synthesis
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7935711B2 (en) 2005-02-18 2011-05-03 Tibotec Pharmaceuticals Ltd. HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
CA2626579A1 (en) 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20080193518A1 (en) * 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
BRPI0715423A2 (pt) 2006-07-21 2013-07-02 Novartis Ag formulaÇÕes para Éteres de benzimidazolil piridila
EP2134689B1 (en) * 2007-03-16 2014-04-23 The Scripps Research Institute Inhibitors of focal adhesion kinase
WO2009100176A2 (en) 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2009105498A1 (en) * 2008-02-19 2009-08-27 Smithkline Beecham Corporation Anilinopyridines as inhibitors of fak
CN102124000B (zh) * 2008-06-17 2014-09-17 阿斯利康(瑞典)有限公司 吡啶化合物
EP2464642A4 (en) 2009-08-12 2013-01-09 Poniard Pharmaceuticals Inc PROCESS FOR PROMOTING APOPTOSIS AND METASTASENHEMMUNG
WO2011133668A2 (en) 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
NZ604801A (en) 2015-03-27
JP5923499B2 (ja) 2016-05-24
ZA201300012B (en) 2013-09-25
MX2012014986A (es) 2013-07-03
US9505719B2 (en) 2016-11-29
CA2803005A1 (en) 2012-01-26
AU2011280031A1 (en) 2013-01-10
JP2013529687A (ja) 2013-07-22
US20140235635A1 (en) 2014-08-21
AU2011280031B2 (en) 2015-09-10
EP2588476A4 (en) 2014-07-23
CN103168037A (zh) 2013-06-19
EP2588476A1 (en) 2013-05-08
WO2012012139A1 (en) 2012-01-26

Similar Documents

Publication Publication Date Title
MX2015000667A (es) Proceso y sistema de reaccion para la preparacion de metanol.
WO2012054364A3 (en) Bicyclic diamines as janus kinase inhibitors
EP4223730A3 (en) Organo-catalytic biomass deconstruction
EP2538979A4 (en) ADHESIVE COMPOSITE KOAZERVATE MANUFACTURED FROM ELECTROSTATICALLY ASSOCIATED BLOCK COPOLYMERS AND METHOD FOR THE PRODUCTION AND USE THEREOF
MX2015000129A (es) Derivados de pirimidin pirazolilo.
WO2012135113A3 (en) Cyclopropylamines as lsd1 inhibitors
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
PH12014502775A1 (en) TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
WO2011090949A3 (en) Methods and compositions for processing chemical reactions
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
MX336607B (es) Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.
MX2012014986A (es) Sintesis y uso de inhibidores de cinasa.
WO2011090694A8 (en) Orally administrable film dosage forms containing ondansetron
EP3312262A4 (en) Reduction burner enabling separate occurrence of oxidation reaction and reduction reaction and synthesis gas recycling system using same
MX350003B (es) Procedimiento para la fabricación de derivados de dibenzoilmetano.
IL326172A (en) Portable system for the production of oxygen
IN2012DN00459A (cg-RX-API-DMAC7.html)
AP2013007133A0 (en) Hydrocarbon synthesis reaction apparatus, start-upprocess thereof and hydrocarbon synthesis reactio n system
IN2015DN02588A (cg-RX-API-DMAC7.html)
PH12017500270A1 (en) Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain
GB2489362B (en) Process for the conversion of synthesis gas
WO2013184570A3 (en) Synthesis of 1,3-substituted aminouracils and other xanthine-related compounds
ZA201304841B (en) Use of the reaction product of a hydrocarbyl-substituted dicarboxylic acid and a nitrogen compound for reducing fuel consumption
WO2011113895A3 (en) Characterization and validation of inhibitors and ligands of dipeptidyl aminopeptidase iv (dp iv)

Legal Events

Date Code Title Description
FG Grant or registration